# Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

> **NCT00047255** · PHASE3 · COMPLETED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 263 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** trastuzumab
- **DRUG:** carboplatin
- **DRUG:** docetaxel
- **BIOLOGICAL:** trastuxumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00047255
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-05
- **Primary completion:** 2006-01
- **Final completion:** 2010-04
- **Target enrollment:** 263 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047255

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047255, "Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00047255. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*